Company Description
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.
It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans.
In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers.
Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jan 27, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Daniel W. Paterson |
Contact Details
Address: 117 Kendrick Street, Suite 500 Needham, Massachusetts 02494 United States | |
| Phone | (781) 292-4200 |
| Website | verastem.com |
Stock Details
| Ticker Symbol | VSTM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001526119 |
| CUSIP Number | 92337C104 |
| ISIN Number | US92337C2035 |
| Employer ID | 27-3269467 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel W. Paterson | President, Chief Executive Officer and Director |
| Daniel Calkins | Chief Financial Officer and Principal Accounting and Financial Officer |
| Richard H. Aldrich M.B.A. | Founder and Consultant |
| Dr. Robert A. Weinberg Ph.D. | Co-Founder and Chair of Scientific Advisory Board |
| Dr. Piyush B. Gupta Ph.D. | Co-Founder |
| Dr. Michelle Dipp M.D., Ph.D. | Co-Founder |
| Robert Pintar M.B.A. | Senior Vice President of Technical Operations |
| Dr. Jonathan Pachter Ph.D. | Chief Scientific Officer |
| Nate Sanburn | Senior Vice President of Corporate Development and External Engagement |
| Dr. Hagop Youssoufian M.D., M.Sc., Ph.D. | Head of Medical Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2024 | 8-K | Current Report |
| Mar 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 14, 2024 | 10-K | Annual Report |
| Mar 11, 2024 | SC TO-I/A | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | SC TO-I | Filing |